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Abstract
Introduction
Preterm birth is associated with increased risk of respiratory symptoms in childhood, often
treated with asthma medication. We designed a follow-up study to previous research and
investigated whether the association of gestational age with purchasing asthma medication
diminishes in adulthood.
Methods
We conducted a register-based study of a national cohort of all infants born in Denmark in
1980–2009 evaluating longitudinal data on individually prescribed asthma medication (both
inhaled ß-2 receptor agonist and different controller treatment over 2-year periods) available
from 1995–2011. We analyzed the effect of gestational age considering age, birth year, and
perinatal variables using logistic regression with a Generalized Estimating Equations model.
All data were unambiguously linked through the Civil Registration System.
Results
We included 1,819,743 individuals in our study population. We found an inverse dose-
response relationship between gestational age and asthma medication in earlier age-groups
with a gradual decrease in odds ratios with increasing age and loss of statistical significance
in early adulthood (18–31 years). For our oldest generations, there was a significant effect
of gestational age (p-value = 0.04), which became insignificant when adjusting for confound-
ing and mediating factors (p = 0.44). There were significant interactions between gestational
age and age (p<0.0001) and gestational age and birth year, but these were most important
during childhood (0–11 years) and for our youngest generations (born after 1995).
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Conclusion
The strong association between gestational age and purchase of prescription asthma medi-
cation weakens with age into early adulthood, in consistence with the results from our previ-
ous study. The risk for purchasing medication to treat asthma-like symptoms was higher in
more recent birth years, but the effect of gestational age was small beyond 11 years of age.
Gestational age per se did not seem to be significant for the development of asthma-like
symptoms: most of its effect could be explained by other perinatal factors.
Introduction
Individuals born preterm experience increased respiratory symptoms later in life [1], often
reported and treated as asthma, although the underlying pathophysiologic pathways might
prove to be quite different [2]. This is documented by an increased use of prescription asthma
medication—especially during early childhood—compared to their peers born at term [3–5].
In a large cross-sectional register study, we previously demonstrated a clear inverse dose-
response relationship with decreasing gestational age (GA) but the effect seemed to diminish
with age and lose significance in adulthood [5].
Asthma prevalence in the general population, however, is steadily increasing [6], and the
chances of survival for the most ill and most immature infants have increased [7]. Thus, the
weaker association between GA and use of prescription asthma medication in the older
cohorts of our previous study could partly be attributable to the ‘healthy survivor’ effect, i.e.
the older generations of children born preterm may simply be at lower risk of developing asth-
matic symptoms requiring treatment with asthma medication, since the more vulnerable new-
borns were less likely to survive. This confounding by time period is often referred to as a
cohort effect or generations effect [8]. Our previous findings [5] were limited by the risk of
such a cohort effect and the cross-sectional design of that study did not allow a distinction
between an actual decrease of the effect of GA and individuals who were simply born with a
lower risk of asthma in adulthood.
Most follow up studies on respiratory sequelae after prematurity are cross-sectional and
longitudinal trends from early childhood until adulthood are missing [9,10]. However, longi-
tudinal data, repeated measurements on the same individuals and corresponding analyses are
required to reliably reveal the true trends in use of asthma medication throughout childhood,
adolescence and young adulthood and to demonstrate whether the association actually weak-
ens over time. Therefore, we conducted this longitudinal study following birth year cohorts
over time, their individual and repeated use of prescription asthma medication and its associa-
tion with gestational age, under the hypothesis that the association found in early childhood
does not persist into adulthood.
Material and methods
Data sources, access and ethics
We conducted a retrospective longitudinal observational register-based study of a national
cohort of all infants born in Denmark in 1980–2009, created from a database used in a previ-
ous study [5]. The database was formed by linking all social and health entries from the Medi-
cal Birth Registry, the National Patient Register, the Register of Education of the Population
and the Cause of Death Register to individual Central Personal Registration (CPR) numbers,
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which were then anonymized before access was given to the researchers. The Danish registers
are consistently and unambiguously linked on an individual basis as a result of the Civil Regis-
tration System, where a unique CPR number is assigned to each individual at birth and used
for all register entries of social and health services. The data sources for the Danish registers,
their uses and their limitations have previously been thoroughly described [5,11–13]. The data-
base was fully accessible to the researchers in its anonymized form, and the study has been
approved by the Danish Data Protection Agency and Danish Health and Medicines Authority
(Jr.no 2007-41-0806). Danish law does not require individual ethical approval for this kind of
study. The anonymized data are available from Statistics Denmark. Access can be granted to
Danish research environments that are pre-approved by Statistics Denmark or to foreign
researchers with an affiliation to a Danish authorized environment. Whilst we cannot guaran-
tee such an access, we can assist interested institutions in any request in this context. We have
followed the Reporting of studies Conducted using Observational Routinely-collected Data
(RECORD) [14] guidelines and a RECORD statement can be found in S1 Table.
Study population
The study population was based on a cohort including all registered births in Denmark during
the period 01.01.1980–31.12.2009 from the Medical Birth Registry. We excluded individuals
who were stillborn, who had missing data on GA, gender or birth weight, or who had abnor-
mal birth weight values defined as differing more than +/- 5 standard deviations (SD) from ref-
erence mean birth weights [15]. In addition, birth weight was set as missing if inferior to 100 g
or superior to 9000 g and GA was set as missing outside the 23–45 weeks’ range, both under
assumption of misclassification.
Outcome
Data from the Danish National Prescription Registry provided the basis of our outcome assess-
ment. The registry contains data on all purchases of prescription medication from all non-hos-
pital pharmacies available during the period 1995–2011 [16,17]. The outcome, prescription
asthma medication, was defined from Anatomical Therapeutic Chemical (ATC) codes in
agreement with our previous study [5] as either:
• a combination of at least one purchase of inhaled selective ß-2 receptor agonist (R03AC) and
at least two purchases of one of the following other drugs for obstructive airway disease:
inhaled glucocorticoids (R03BA), inhaled anticholinergics (R03BB), teophyllins (R03DA),
oral leukotriene-receptor antagonists (R03DC), systemic steroid (H02AB) or
• at least two purchases of a combination inhaler (R03AK, R03AL).
The outcome was evaluated from every even birthday starting from 0 years and in the fol-
lowing 2-year period (0–1, 2–3 years etc.). Only complete 2-year periods within the time frame
1995–2011 were evaluated. The 2-year period was also censored if the follow-up was not com-
plete due to either death before or during the period or due to residence abroad at the start of
the period or emigration during the 2-year period.
Covariates
• GA: The main exposure of interest was gestational age in full weeks and 4 main groups were
considered: term with GA 37, moderately preterm with GA 32–36, very preterm with GA
28–31 and extremely preterm with GA 23–27 weeks. GA was modelled as an ordinal variable
with 4 levels from term to extremely preterm. Thus, the resulting ORs are for a one unit
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increase in prematurity (e.g. from GA group 32–36 to group 28–31 weeks), with the term
group as the reference. This approach was chosen based on superior goodness-of-fit statistics
compared with a model treating GA as a categorical variable.
• Age groups: Each 2-year observation period was categorized according to the following age
groups: 0–1 (infants), 2–5 (preschoolers), 6–11 (school-aged children), 12–17 (adolescents),
18–23 and 24–31 years (adults) under parametric assumptions.
• Birth year: grouped into 1980–1984, 1985–1989, 1990–1994, 1995–1999, 2000–2004 and
2005–2009 under parametric assumptions.
In addition, we included the following variables with known associations with preterm birth
and asthma in the analysis:
• Birth weight (BW): Small-for-gestational-age (SGA) was defined as a BW< -2 SD from Mar-
sa´l’s reference value [15].
• Sex.
• Firstborn.
• Multiple birth.
• Delivery method: vaginal birth or cesarean section (emergency and elective).
• Maternal educational level: evaluated at time of birth and divided into three groups per the
International Standard Classification of Education 2011 (ISCED) [18]. Group 1 included
ISCED levels 0–2, group 2 levels 3–4 and group 3 levels 5–8. When information on maternal
educational level was missing, data on paternal educational level were used instead.
• Maternal asthma and atopy medication: Asthma medication followed the same definition
as the outcome and was evaluated in a 2-year period prior to birth. Since data were only
available from 1995, for births before 1997, a 2-year period beginning in 1995 was used to
supply data as close to birth as possible. Atopy medication was defined as at least one pur-
chase of prescribed (ATC-codes): nasal steroid spray (R01AD), facial steroid cream group I
(D07AA), steroid cream group III (D07AC) during the same 2-year period.
• Neonatal respiratory morbidity: assessed from admission data during the first 6 months after
birth. The diagnoses used for acute neonatal respiratory disease were (International Classifi-
cation of Diseases codes): respiratory distress and transitory tachypnea of the neonate (ICD-
8 776.290/ICD-10 P22.1 and P22.8), respiratory distress syndrome (ICD-8 776.190/ICD-10
P22.0) and neonatal emphysema (ICD-8 776.200/ICD-10 P25.0). The diagnoses included for
chronic neonatal respiratory disease were pulmonary fibrosis (ICD-8 517.010) before 1994
and bronchopulmonary dysplasia (BPD) (ICD-10 P27.1) after the 1994 classification system
change.
• Maternal smoking during pregnancy: self-reported at prenatal visits. The variable was avail-
able from 1991 (only evaluated in a sub-group analysis).
Statistical analyses
We analyzed our primary outcome using a logistic regression on the binomial asthma medica-
tion outcome. All valid outcome measurements from all individuals were analyzed together,
and intra-person dependence was accounted for by using Generalized Estimating Equations
(GEE) with an autoregressive working correlation matrix. Thereby, the GEE model allows for
Young adults born preterm do not have an increased use of asthma medication
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several measurements on the same individual to be analyzed together—which is not normally
possible due to assumptions of independency—while correcting for potential correlation
between measurements on the same individual. The repeated measures allow for an individual
follow-up on a potentially decreasing asthma medication purchase over time. Analyses were
carried out in two different models:
• Model 1: adjusted for GA, age, year of birth and both interactions between GA and age
groups and GA and birth year groups respectively.
• Model 2: as model 1 + variables present at birth (SGA, sex, siblings, multiple birth, delivery
method, maternal educational level, maternal asthma and atopy medication) and variables
from the neonatal period (acute and chronic neonatal respiratory morbidity).
Observations with missing data in the explanatory variables in model 2 were censored in
the analyses.
The model 2 analysis was also done on a subgroup from the later years with data available
on maternal smoking during pregnancy to explore the effect of this potential confounder.
All data management, analyses and graphic illustrations were performed in SAS Statistical
Software (version 9.4, SAS Institute, USA).
Results
Study population
A total of 1,819,743 individuals (86% of all registered births from 1980–2009) were included in
the study population after the exclusion criteria described in Fig 1. The baseline characteristics
are described in Table 1. BPD was linked to extreme prematurity (31.5% for GA 23–27 com-
pared to 4.0% for GA 28–31, 0.04% for GA 32–36 and 0.0% for GA 37+), whereas acute neona-
tal respiratory disease also occurred in milder degrees of prematurity (18.2% in moderately
preterm, 61.6% in very preterm and 77.0% in extremely preterm). Maternal factors such as
asthma medication (5.1–6.2%), atopy medication (14.3–18.6%), and smoking (22.2–28.9%)
showed smaller differences in distribution.
The distribution of missing values in the study population is described in Table 2.
Statistical analyses
The extraction of data on the outcome purchase of prescription asthma medication yielded a
total of 10,521,952 2-year period observations for the included 1,819,743 individuals, of which
299,728 (2.8%) 2-year periods were censored due to emigration or death. Of the non-censored
observations, 448,728 (4.4%) were registered as positive for asthma medication.
The inverse dose-response relationship between GA and the crude rate of purchase of pre-
scription asthma medication was consistent across all age groups, although the gradient
decreased markedly during childhood (Fig 2).
The number of observations varied among the birth cohorts and calendar years since medi-
cation data was only available from 1995 and considering the latest birth cohorts only had a
limited period of observation (Fig 3).
We first explored the effect of GA per se using the GEE model 2 with the GA groups as a cat-
egorical variable to allow for independent estimates of effects. The adjusted analysis supports
the findings from our descriptive analyses, illustrating a higher odds-ratio (OR) for more pre-
term GA-groups until age 12–17 years, a gradual decrease in ORs with age and loss of statisti-
cal significance in early adulthood (Fig 4).
Young adults born preterm do not have an increased use of asthma medication
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Fig 1. Flow-chart with exclusions from national birth cohort to final study population. CPR: Central Personal
Registration, GA: gestational age, BW: birth weight.
https://doi.org/10.1371/journal.pone.0199884.g001
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Next, GA was modelled as an ordinal variable, i.e. the GA groups as a variable with four
steps. In Table 3, the main effect of age demonstrates that across the board, the risk of respira-
tory symptoms with asthma medication purchase decreases with age. Because the reference
was set as 24–31 years for the age variable and years 1980–1984 for the birth year variable, the
main effect of GA (p = 0.44 in model 2) corresponds to the effect of GA at 24-31-years in indi-
viduals born 1980–1984. In model 1, GA showed a marginally significantly increased risk of
asthma medication purchase for the oldest generations (p-value = 0.04).
The interaction terms GAage (p-value<0.0001) and GAbirth year (p-value 0.001) were
significant overall. We found a substantial effect of GA in children below 12 years of age and
from birth year 1995 (ORs 1.33, 1.33 and 1.14 for age groups 0, 2–5 and 6–11 respectively and
1.12, 1.11 and 1.10 for birth years 2005–2009, 2000–2004 and 1995–1999 respectively), while it
was marginal for older individuals and earlier birth years (Table 3).
Sub-group analyses
The sub-group-analysis on individuals with available data on maternal smoking during preg-
nancy demonstrated that this potential confounder had only little effect. The data consisted of
Table 1. Baseline characteristics of final study population in %.
GA 37+
(n = 1,717,214)
GA 32–36
(n = 89,540)
GA 28–31
(n = 10,631)
GA 23–27
(n = 2,381)
Male sex 51.1 54.4 54.8 52.2
SGA 3.0 10.9 20.3 12.8
Cesarean section 13.9 39.4 65.6 54.0
Multiple birth 2.0 22.7 30.4 28.5
First born 44.8 53.7 58.2 60.5
BPD 0.0 0.04 4.0 31.5
Acute neonatal respiratory disease 1.7 18.2 61.6 77.0
Maternal educational level (ISCED) 0–2 37.6 40.2 40.1 41.3
3–4 36.1 36.8 37.3 35.8
5–8 26.3 23.0 22.7 22.8
Maternal asthma medication 5.1 5.4 6.2 5.6
Maternal atopy medication 18.6 15.9 14.7 14.3
Maternal smoking 22.2 26.9 28.9 26.7
https://doi.org/10.1371/journal.pone.0199884.t001
Table 2. Distribution of missing values in final study population in crude numbers (%).
First born
n (%)
Multiple birth
n (%)
Cesarean section
n (%)
Maternal educational level
n (%)
Maternal smoking
n (%)
Total 4906 (0.3) 21 (0.0) 2614 (0.1) 14,029 (0.8) 638,050 (35.1)
By birth year group 1980–1984 0 (0.0) 1 (0.0) 1845 (0.8) 3098 (1.3) 243,465 (100)
1985–1989 1 (0.0) 4 (0.0) 433 (0.2) 3073 (1.1) 281,384 (100)
1990–1994 0 (0.0) 2 (0.0) 127 (0.0) 2567 (0.8) 80,499 (24.8)
1995–1999 562 (0.2) 13 (0.0) 91 (0.0) 1882 (0.6) 16,881 (5.1)
2000–2004 609 (0.2) 1 (0.0) 109 (0.0) 1044 (0.3) 8466 (2.6)
2005–2009 3734 (1.2) 0 (0.0) 9 (0.0) 2365 (0.7) 7355 (2.3)
By gestational age group 37+ 4325 (0.3) 14 (0.0) 2419 (0.1) 13,253 (0.8) 605,081 (35.2)
32–36 478 (0.5) 4 (0.0) 156 (0.1) 696 (0.8) 28,697 (32.1)
28–31 87 (0.8) 0 (0.0) 33 (0.3) 68 (0.6) 3558 (33.5)
23–27 16 (0.7) 3 (0.1) 6 (0.3) 12 (0.5) 714 (30.0)
https://doi.org/10.1371/journal.pone.0199884.t002
Young adults born preterm do not have an increased use of asthma medication
PLOS ONE | https://doi.org/10.1371/journal.pone.0199884 July 5, 2018 7 / 15
5,844,148 observations from 1,181,693 individuals born from 1991–2009 which were analyzed
with the GEE model 2 both with and without the smoking variable (S2 Table). While maternal
smoking showed an adjusted OR of 1.25 (95% confidence interval (CI) 1.24–1.27), inclusion of
the variable did not alter the effect size of the other variables considerably. In agreement with
main analyses, there was no significant effect of GA in the oldest group (18–19 years of age)
and a steady decrease in risk of asthma medication purchase with age was observed. It is
important to note, that this sub-group had almost complete outcome measurements from
birth for all individuals, ie. they do not lack baseline measurements for the oldest generations.
Discussion
In this unique longitudinal large dataset, we confirmed our previous findings from the cross-
sectional evaluation of the association between GA and purchase of prescription asthma medi-
cation [5]: the strong association found between GA and purchase of prescription asthma
medication in childhood weakens with age and largely disappears in adulthood. Importantly,
our current findings imply that the weakening of this association did not seem to be due sim-
ply to a cohort effect: the interaction terms between GA and birth year were statistically signifi-
cant only from 1995 and onwards. In the same manner, the interaction between GA and age
was statistically significant up to 11 years of age only. The birth year variable did however
Fig 2. The inverse dose-response relationship between GA groups and asthma medication (in %) decreases and weakens with age. GA: gestational age.
https://doi.org/10.1371/journal.pone.0199884.g002
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show a doubling of asthma risk over the time period studied (OR 2.27 in 2005–2009, compared
to 1980–1984), confirming the trend in asthma prevalences throughout the follow-up period
[6].
The estimate for the crude risk in 24-31-year-olds was small: +9% per GA group (OR 1.09,
95% CI 1.01–1.18). The adjusted risk was independent of GA.
Although children born preterm have a documented higher risk of respiratory complaints
[3], the decrease in association with GA during childhood might in part be related to improved
clinical assessment by diagnostic tools such as lung function (spirometry), which are typically
feasible from school age and onwards. Lung function assessment could indicate to the clinician
that the respiratory complaints of individuals born preterm are not necessarily similar to clas-
sical atopic asthma. They would therefore often be unresponsive to such medication. Further-
more, some children born preterm may “outgrow” their respiratory symptoms, for example
due to the catch-up alveolarization phenomenon [19]. In other words, the changes in asthma
medication over time could either be due to increased availability of diagnostic tools and the
ensuing more specific evaluation of treatment responses or to improved airway function with
age–if not objectively then subjectively. It is interesting to note however, that new research
points to a tracking of airway function in individuals born extremely preterm, revealing
Fig 3. Distribution of number of observations on 2-year age periods by birth year groups. Illustration of the different follow-up age periods according to birth year
during the follow-up period 1995–2011.
https://doi.org/10.1371/journal.pone.0199884.g003
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persistent substantial airflow limitation and impaired airway function, both in individuals
with and without BPD [20,21].
The presence of a GA effect in young adults in model 1 (the crude risk), but absence in
model 2 (adjusted for all available potential confounding and modifying variables) suggests
that GA per se is not a significant risk factor for asthma medication purchase in adolescence
and young adulthood. In fact, it seems that the increase in crude risk is explained by factors
associated with the prenatal period or birth (maternal factors including atopic predispositions,
smoking, mode of delivery, sex, birth weight), and by factors of the neonatal period (respira-
tory distress and BPD). Maternal use of atopy medication and asthma medication (OR 1.37
and 5.57 respectively) and neonatal respiratory disease (OR 1.24 for acute disease and 1.44 for
BPD) seemed to be particularly strongly associated with the outcome. Put another way, these
factors may play a more significant role in determining an individual’s risk of later pulmonary
sequelae requiring anti-asthmatic treatment than the fact of being born preterm in itself. Indi-
viduals with these risk factors might still be at increased risk of impaired pulmonary function
in both child- and adulthood.
Fig 4. ORs for purchase of prescription asthma medication in age groups per GA-group illustrating gradual decrease of the GA-effect to loss of statistical
significance in adulthood. The reference was GA 37+ at age 24–31. Adjusted for birth year, sex, SGA, maternal atopy and asthma medication, maternal educational
level, cesarean section, older sibling, acute and chronic neonatal respiratory disease and interactions GAage group and GA birth year. OR: odds-ratio, GA:
gestational age.
https://doi.org/10.1371/journal.pone.0199884.g004
Young adults born preterm do not have an increased use of asthma medication
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The observational nature of the study does not permit an exploration of the causal pathways
and BPD remains a major risk factor for persistent decreased lung function and pulmonary
impairment, presumably throughout life, which emphasizes the need for a continuous follow-
up in order to explore the risk for COPD later in life regardless of BPD type (“old” vs. “new”)
[22–24].
The important strengths of the study are the inclusion of an almost complete nationwide
birth cohort and the access to emigrational data and death both in the country and abroad,
resulting in reliable censoring. The Danish National Prescription Registry provides high-
Table 3. ORs main analyses.
Model 1 Model 2
OR (95% CI) Type-III test (p-value) OR (95% CI) Type-III test (p-value)
GA (per increase in group) 1.09 (1.01–1.18) 0.04 0.97 (0.90–1.05) 0.44
Age in years (reference: 24–31 years) 0 1.33 (1.23–1.45) <0.0001 1.34 (1.24–1.46) <0.0001
2–5 1.02 (0.94–1.10) 1.01 (0.93–1.09)
6–11 1.05 (0.98–1.14) 1.05 (0.97–1.13)
12–17 1.17 (1.09–1.26) 1.18 (1.09–1.26)
18–23 0.95 (0.89–1.02) 0.95 (0.89–1.01)
Birth year (reference: 1980–1984) 1985–1989 0.96 (0.88–1.05) <0.0001 0.96 (0.87–1.05) <0.0001
1990–1994 0.98 (0.89–1.06) 1.02 (0.93–1.11)
1995–1999 1.05 (0.96–1.14) 1.21 (1.11–1.31)
2000–2004 1.24 (1.14–1.35) 1.51 (1.38–1.64)
2005–2009 1.89 (1.73–2.06) 2.27 (2.08–2.48)
Age  gestational age (reference: 24–31 years) 0 1.33 (1.23–1.43) <0.0001 1.36 (1.26–1.46) <0.0001
2–5 1.33 (1.24–1.43) 1.36 (1.26–1.46)
6–11 1.14 (1.06–1.22) 1.15 (1.07–1.24)
12–17 1.04 (0.97–1.11) 1.04 (0.98–1.11)
18–23 1.03 (0.97–1.09) 1.04 (0.98–1.10)
Birth year  gestational age (reference: 1980–1984) 1985–1989 1.02 (0.94–1.11) 0.02 1.02 (0.94–1.10) 0.001
1990–1994 1.07 (0.99–1.16) 1.03 (0.95–1.11)
1995–1999 1.10 (1.02–1.19) 1.11 (1.03–1.20)
2000–2004 1.11 (1.03–1.20) 1.10 (1.02–1.19)
2005–2009 1.12 (1.04–1.21) 1.12 (1.04–1.21)
Female sex NA 0.72 (0.72–0.73) <0.0001
Small for gestational age NA 1.09 (1.06–1.12) <0.0001
Maternal atopy medication NA 1.37 (1.35–1.38) <0.0001
Maternal asthma medication NA 5.57 (5.48–5.65) <0.0001
Maternal educational level (reference: ISCED 0–2) ISCED 3–4 NA 1.00 (0.99–1.01) <0.0001
ISCED 5–8 0.94 (0.93–0.95)
Cesarean section NA 1.13 (1.12–1.15) <0.0001
First born NA 1.03 (1.02–1.04) <0.0001
Acute neonatal respiratory disease NA 1.24 (1.21–1.28) <0.0001
BPD NA 1.44 (1.28–1.63) <0.0001
Estimates are adjusted for the other variables in the model.
OR: odds-ratio
95% CI: 95% confidence interval
NA: not applicable (not included in model)
: interaction between separate links.
https://doi.org/10.1371/journal.pone.0199884.t003
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quality data on all purchases of prescription medication: purchases are automatically registered
from all out-of-hospital pharmacies and digitally reported to the Danish Health Authority, and
the records form the basis for the Danish medication reimbursement system [25]. Data are
directly linked with the patient’s CPR number. In-hospital pharmacies are not included in the
database but have no sales. Therefore, only medications delivered at discharge would be miss-
ing in the database. Although the data were not originally collected for research purposes, all
these factors provide excellent external validity with low risk of misclassification and loss of
data. The concordance between questionnaire-based data and register data is high and has
been studied specifically for asthma medication in children [26]. The only self-reported vari-
able in the study was maternal smoking during pregnancy. The percentage of missing values
was low and homogeneously distributed except for the smoking variable (available only from
1991 and onward). There are no records of personal smoking history available in the Danish
registers.
The most important weaknesses are that the purchase of asthma and atopy medication was
used as a proxy for asthma-like symptoms and atopic disease respectively. However, purchase
of asthma medication has previously been validated as a good method for identifying asth-
matic school children with a high specificity [27]. Furthermore, the definition of our outcome
aimed at studying the more severe end of the disease spectrum. This strict outcome definition
also deals with the unknown factor of patient compliance under the assumption, that a patient
who has used a prescription more than once or used different drugs is considered more likely
to have actively used the prescribed drug. Though the definition of fixed 2-year periods (start-
ing every even birthday) may have lowered the prevalences further, we believe that it only con-
tributed to increasing the outcome reliability. The beginning of medication registration in
1995 also resulted in a lack of baseline asthma medication data for the oldest generations of the
study (Fig 3), which prevents a complete study of the trend in GA-effect in these individuals.
However, agreement between our main analyses and sub-group analyses with baseline-mea-
surements for almost all children implies that the lack of some baseline measurements in the
main analysis should not affect the results. Similarly, it was not possible to include other poten-
tially confounding factors such as maternal antibiotic use, which introduces the risk of residual
confounding. Finally, as the chance of survival of extremely preterm infants was small [28], the
oldest generations in our study had only few individuals born extremely preterm (0.1% of the
study population) and constituted a smaller part of the study population due to growing birth
numbers. The improvement of survival after preterm birth during the study period might neg-
atively affect the generalizability of the study. This could be indicated by the interaction
between GA and birth year, but since the youngest age groups of the study population have
not yet reached adulthood, we cannot yet conclude on this aspect.
Conclusion
In this longitudinal study, we did not find an association between GA and purchase of asthma
medication in older age groups, consistent with our prior belief that the effect of GA towards
the risk of asthma diminishes with age. It remains to be investigated if this association will
recur in later adulthood and whether it is prematurity per se or rather neonatal respiratory dis-
ease that increases the risk of pulmonary impairment later in life.
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